Survival of patients with ruptured gastrointestinal stromal tumour treated with adjuvant imatinib in a randomised trial

CONCLUSIONS: About one-fifth of ruptured GISTs treated with adjuvant imatinib did not recur during the first decade of follow-up. Relatively high OS rates were achieved despite …